STOCK TITAN

Establishment Labs Holdings Inc. - ESTA STOCK NEWS

Welcome to our dedicated page for Establishment Labs Holdings news (Ticker: ESTA), a resource for investors and traders seeking the latest updates and insights on Establishment Labs Holdings stock.

Establishment Labs Holdings Inc. (ESTA) is a leading global medical technology company, renowned for its innovation in the field of medical devices and aesthetics. Specializing in advanced silicone-filled breast and body shaping implants, the company has over 30 years of experience in breast implant manufacturing. Establishment Labs designs, develops, manufactures, and markets an extensive product portfolio that ensures safety and meets the current needs and preferences of plastic surgeons and patients.

Known for its flagship product, Motiva Implants®, Establishment Labs has set a benchmark in the industry for product innovation and safety. The company operates in multiple geographical segments, including Europe, Latin America, Asia-Pacific/Middle East, and other regions. Establishment Labs' products are distributed to medical distributors, physicians, hospitals, and clinics through direct sales channels.

Recent achievements include the continued global expansion of the Motiva Implants® brand and strategic partnerships aimed at advancing medical and aesthetic technology. With a strong focus on the future, the company is dedicated to pushing the boundaries of innovation and safety in medical devices.

Establishment Labs maintains a robust financial condition, driven by its commitment to quality and continuous improvement. The company’s ongoing projects include research and development initiatives aimed at introducing new and improved products that align with market demands.

For the latest updates and relevant information about Establishment Labs Holdings Inc., stay tuned to this page for the most recent news and developments.

Rhea-AI Summary

Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced its participation in two investment conferences. CEO Juan José Chacón-Quirós and Interim CFO Raj Denhoy will attend the Jefferies London Healthcare Conference on November 16, 2021, and the Canaccord Genuity Virtual MedTech Forum on November 18, 2021. Live webcasts of their presentations will be available on the Establishment Labs investor relations website, with archived versions accessible afterward. The company specializes in breast aesthetics and reconstruction, offering innovative silicone gel-filled implants globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
none
-
Rhea-AI Summary

Establishment Labs Holdings Inc. (NASDAQ: ESTA) reported third-quarter 2021 revenue of $29.0 million, up 27.6% year-over-year. Gross profit margin improved to 67.6%, while operating expenses increased to $28.7 million, driven by a return to normal business conditions. The company raised its 2021 revenue guidance to $124 million to $128 million, a growth of 46% to 51% over 2020. A net loss of $9.0 million was recorded. The company launched the Motiva Flora® tissue expander, and its Motiva implants are on track for U.S. and China market entry.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.55%
Tags
-
Rhea-AI Summary

Establishment Labs Holdings Inc. (NASDAQ: ESTA) has appointed Jeffrey Bettinger as Global Head of People. Bettinger, previously Chief People and Places Officer at Nu Skin, joins the executive team with a focus on culture and human capital strategy. CEO Juan José Chacón-Quirós emphasized the importance of people and culture for the company's upcoming growth and global expansion. Measuring past success in leadership development, Bettinger aims to innovate within the Femtech industry to positively impact women's lives. Establishment Labs specializes in breast aesthetics and has delivered over 1.8 million Motiva Implants in 80+ countries.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
none
Rhea-AI Summary

Establishment Labs Holdings Inc. (NASDAQ: ESTA) will announce its financial results for Q3 2021 on November 9, 2021, before market opens. Following this, a conference call is scheduled at 8:30 AM ET to discuss the results. Establishment Labs specializes in women's health, particularly in breast aesthetics and reconstruction, offering products like Motiva Implants®. Since 2010, over 1.6 million implants have been distributed worldwide in over 80 countries. The company is focused on regulatory approvals for its innovative products.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.32%
Tags
-
News
Rhea-AI Summary

Establishment Labs Holdings Inc. (NASDAQ: ESTA) launched JOY™, a new patient-centric breast aesthetics program featuring the latest Motiva Ergonomix2® implants. JOY offers comprehensive support, including the Motiva Woman’s Choice Program™, which provides financial assistance for implant removal, and surgeon options for reverse procedures at no additional cost. Announced at the 6th World Symposium on Ergonomic Implants in Italy, JOY aims to enhance the experience for women undergoing breast surgery by combining advanced implant technology with specialized surgeon training.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
none
-
Rhea-AI Summary

Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced its support for Breast Cancer Awareness Month in October, focusing on improving access to breast reconstruction. The company will implement the Pink is for Power program in Brazil, providing 200 women with reconstruction surgeries. Key events planned include the Motiva Breast Health Day in Barcelona and the Rosé for Reconstruction event in Italy. With the recent launch of their Motiva Flora tissue expander, Establishment Labs aims to enhance clinical outcomes for breast cancer patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.54%
Tags
none
Rhea-AI Summary

Establishment Labs Holdings Inc. (NASDAQ: ESTA) officially launched its Motiva Flora® tissue expander in Europe during a symposium at the London Breast Meeting on September 2, 2021. This RFID-enabled device aims to enhance post-mastectomy reconstruction, improving patient comfort through advanced biocompatibility and MRI imaging capabilities. CEO Juan José Chacón-Quirós highlighted the significance of Flora in capturing a substantial market share in breast reconstruction, projecting improved outcomes for women. Motiva Flora is not yet approved for distribution in the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.96%
Tags
none
-
Rhea-AI Summary

Establishment Labs Holdings Inc. (NASDAQ: ESTA) has announced the launch of Motiva Flora®, a new tissue expander in Europe and CE Mark countries, set for September 2, 2021. This innovative product features patented SmoothSilk® surface technology and RFID-enabled ports, aiming to enhance imaging and patient outcomes. The event will include presentations from medical professionals and discussion on commercialization plans. Currently, Motiva Flora is not approved for distribution in the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.86%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.1%
Tags
none
Rhea-AI Summary

Establishment Labs Holdings Inc. (NASDAQ: ESTA) has announced participation in the UBS Genomics 2.0 and MedTech Innovations Summit from August 10-12, 2021. CEO Juan José Chacón-Quirós and Interim CFO Raj Denhoy will address attendees on August 12 at 8:00 am ET. A live webcast of their presentation will be available on the company's investor relations website, along with an archived version post-event. Establishment Labs specializes in women's health, notably breast aesthetics and reconstruction, marketing over 1.6 million Motiva Implants® worldwide since 2010.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.05%
Tags
none

FAQ

What is the current stock price of Establishment Labs Holdings (ESTA)?

The current stock price of Establishment Labs Holdings (ESTA) is $40.01 as of December 20, 2024.

What is the market cap of Establishment Labs Holdings (ESTA)?

The market cap of Establishment Labs Holdings (ESTA) is approximately 1.1B.

What does Establishment Labs Holdings Inc. specialize in?

Establishment Labs specializes in designing, developing, manufacturing, and marketing advanced silicone-filled breast and body shaping implants.

What is the flagship product of Establishment Labs?

The flagship product of Establishment Labs is Motiva Implants®, known for its safety and innovation.

In which regions does Establishment Labs operate?

Establishment Labs operates in Europe, Latin America, Asia-Pacific/Middle East, and other regions.

How does Establishment Labs distribute its products?

The company distributes its products through direct sales to medical distributors, physicians, hospitals, and clinics.

What are the recent achievements of Establishment Labs?

Recent achievements include global expansion of the Motiva Implants® brand and strategic partnerships to advance medical and aesthetic technology.

What is the focus of Establishment Labs' ongoing projects?

Ongoing projects focus on research and development to introduce new and improved products that meet market demands.

How long has Establishment Labs been in the breast implant manufacturing industry?

Establishment Labs has over 30 years of experience in the breast implant manufacturing industry.

What sets Motiva Implants® apart from other products in the market?

Motiva Implants® are known for their innovation, safety, and alignment with the needs and preferences of plastic surgeons and patients.

Is Establishment Labs a publicly traded company?

Yes, Establishment Labs Holdings Inc. is a publicly traded company with the symbol ESTA.

Where can I find the latest news about Establishment Labs Holdings Inc.?

You can find the latest news and updates about Establishment Labs Holdings Inc. on this webpage and from reliable financial news sources.

Establishment Labs Holdings Inc.

Nasdaq:ESTA

ESTA Rankings

ESTA Stock Data

1.12B
25.28M
11.28%
98.89%
17.16%
Medical Devices
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States of America
ALAJUELA